

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

BEFORE THE PATENT TRIAL AND APPEAL BOARD

ARGENTUM PHARMACEUTICALS LLC,
Petitioner,

v.

RESEARCH CORPORATION TECHNOLOGIES, INC.,
Patent Owner.

Case No. IPR2016-00204
Patent No. RE 38,551

PATENT OWNER'S EXHIBIT LIST

LIST OF EXHIBITS


| Exhibit | Description |
|---------|---|
| 2001 | Richard H. Mattson, <i>Efficacy and Adverse Effects of Established and New Antiepileptic Drugs</i> , 36 (Suppl. 2) <i>Epilepsia</i> S13-S26 (1995). |
| 2002 | Richard H. Mattson, <i>Drug Treatment of Uncontrolled Seizures, in Surgical Treatment of Epilepsy</i> 29-35 (William H. Theodore ed., 1992). |
| 2003 | FDA Approved Labeling Text dated August 27, 2012 for FELBATOL [®] (felbamate), available at http://www.accessdata.fda.gov/drugsatfda_docs/label/2012/020189s0271bl.pdf (last visited Feb. 2, 2016). |
| 2004 | Judith D. Conley & Harold Kohn, <i>Functionalized DL-Amino Acid Derivatives. Potent New Agents for the Treatment of Epilepsy</i> , 30 <i>J. Med. Chem.</i> 567-574 (1987). |
| 2005 | U.S. Provisional Patent Application No. 60/013,522. |
| 2006 | Bialer <i>et al.</i> , <i>Progress report on new antiepileptic drugs: a summary of the Sixth Eilat Conference (EILAT VI)</i> , 51 <i>Epilepsy Res.</i> 31-71 (2002). |
| 2007 | Jerry March, <i>Advanced Organic Chemistry</i> 94-96 (4th ed. 1992). |
| 2008 | Decision Denying Institution of <i>Inter Partes</i> Review, IPR2014-01126, Paper 22. |
| 2009 | Curriculum Vitae of Dr. Farrokh Mistree, September 2014. |
| 2010 | Marcy Barge & W.T. Ingram, <i>Inverse Limits on [0,1] Using Logistic Bonding Maps</i> , 72 <i>Topology and its Applications</i> 159-72 (1996). |
| 2011 | Jack McBryde Jr., <i>Inverse Limits on Arcs Using Certain Logistic Maps as Bonding Maps</i> , Master's Thesis, University of Houston, (1987). |
| 2012 | Trial Testimony of Dr. Clayton Heathcock, <i>UCB, Inc., et al., v. Accord Healthcare, Inc., et al.</i> , No. 13-1206-LPS (D. Del., Nov. 9, 2015). |

| Exhibit | Description |
|---------|---|
| 2013 | FDA Approved Labeling Text dated July 9, 2015 for VIMPAT [®] (lacosamide), <i>available at</i> http://www.accessdata.fda.gov/drugsatfda_docs/label/2015/022253s030,022254s022,022255s016lbl.pdf (last visited Feb. 2, 2016). |
| 2014 | Wolfgang Löscher & Dieter Schmidt, <i>Strategies in Antiepileptic Drug Development: Is Rational Drug Design Superior to Random Screening and Structural Variation?</i> , 17 <i>Epilepsy Research</i> 95-134 (1994). |
| 2015 | Michael A. Rogawski & Roger J. Porter, <i>Antiepileptic Drugs: Pharmacological Mechanisms and Clinical Efficacy with Consideration of Promising Developmental Stage Compounds</i> , 42(3) <i>Pharmacological Reviews</i> 223-86 (1990). |
| 2016 | John M. Pellock, <i>Standard Approach to Antiepileptic Drug Treatment in the United States</i> 35 (Suppl. 4) <i>Epilepsia</i> S11-S18 (1994). |
| 2017 | Approval Listing dated December 27, 1994 for lamotrigine, Approved Drug Products with Therapeutic Equivalence Evaluations (Electronic Orange Book), http://www.accessdata.fda.gov/scripts/cder/ob/docs/obdetail.cfm?Appl_No=020241&TABLE1=OB_Rx (last visited Feb. 2, 2016). |
| 2018 | The Merck Index 77, 290, 404, 407, 408, 508, 640, 670, 733, 915, 998, 999, 1020, 1028, 1207, 1246, 1247, 1251, 1259, 1260, 1330, 1654 (Susan Budavari et al. eds., 12th ed. 1996). |
| 2019 | Approval Listing dated August 5, 1996 for fosphenytoin sodium, Approved Drug Products with Therapeutic Equivalence Evaluations (Electronic Orange Book), http://www.accessdata.fda.gov/scripts/cder/ob/docs/obdetail.cfm?Appl_No=020450&TABLE1=OB_Rx (last visited Feb. 2, 2016). |
| 2020 | FDA Approved Labeling Text dated January 2014 for CEREBYX [®] (fosphenytoin sodium injection) , <i>available at</i> http://www.accessdata.fda.gov/drugsatfda_docs/label/2014/020450s023lbl.pdf (last visited Feb. 2, 2016). |

| Exhibit | Description |
|---------|---|
| 2021 | ChemIDPlus, Toxnet, U.S. Nat'l Library of Medicine, Beclamide, http://chem.sis.nlm.nih.gov/chemidplus/rn/501-68-8 (last visited Feb. 2, 2016). |
| 2022 | ChemIDPlus, Toxnet, U.S. Nat'l Library of Medicine, Phenacemide, http://chem.sis.nlm.nih.gov/chemidplus/rn/63-98-9 (last visited Feb. 2, 2016). |
| 2023 | ChemIDPlus, Toxnet, U.S. Nat'l Library of Medicine, Valproic acid, http://chem.sis.nlm.nih.gov/chemidplus/rn/99-66-1 (last visited Feb. 2, 2016). |
| 2024 | Portfolio – Mont Alto Capital, http://www.montaltocapital.com/portfolio/ (last visited Feb. 23, 2016). |
| 2025 | Trial Transcript, <i>UCB, Inc., et al., v. Accord Healthcare, Inc., et al.</i> , No. 13-1206-LPS (D. Del., Nov. 9-13, 2015). (served, but not filed, March 17, 2016) |
| 2026 | PTAB Telephonic Conference Transcript, IPR2016-00204 (March 8, 2016). |
| 2027 | PTAB Telephonic Conference Transcript, IPR2016-00204 (April 4, 2016). |
| 2028 | PTAB Email to Counsel of Record (January 12, 2016) |

Dated: April 18, 2016

Respectfully submitted,

By 

COVINGTON & BURLING LLP
 One CityCenter
 850 Tenth Street NW
 Washington, DC 20001
 (202) 662-6000


Andrea G. Reister
 Registration No.: 36,253
 Jennifer L. Robbins
 Registration No.: 61,163
 Enrique D. Longton
 Registration No.: 47,304
 Attorneys for Patent Owner

CERTIFICATE OF SERVICE

Pursuant to 37 C.F.R. § 42.6, I hereby certify that on this 18th day of April 2016, the foregoing **Patent Owner's Exhibit List and Exhibits 2027-2028** were served by electronic mail, by agreement of the parties, on the following counsel of record for Petitioner:

Matthew J. Dowd (MatthewDowd@andrewskurth.com)
Justin W. Crotty (JustinCrotty@andrewskurth.com)
Andrews Kurth LLP
1350 I Street, NW, Suite 1100
Washington DC 20005

Dated: April 18, 2016


Andrea G. Reister, Esq.
Registration No. 36,253